This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj)
Medical Information
RYBREVANT FASPRO - Vial Overfill
Last Updated: 06/22/2026
SUMMARY
- RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for subcutaneous (SC) administration is a coformulation of amivantamab with recombinant human hyaluronidase PH20 (rHuPH20).1
- Each RYBREVANT FASPRO 10 mL single-dose vial (amivantamab 1600 mg) has an overfill volume of 1.2 mL (for the current commercial manufacturing site).2
- Each RYBREVANT FASPRO 14 mL single-dose vial (amivantamab 2240 mg) has an overfill volume of 1.3 mL (for the current commercial manufacturing site).2
- Each RYBREVANT FASPRO 15 mL single-dose vial (amivantamab 2400 mg) has an overfill volume of 1.3 mL (for the current commercial manufacturing site).3
- Each RYBREVANT FASPRO 22 mL single-dose vial (amivantamab 3520 mg) has an overfill volume of 1.4 mL (for the current commercial manufacturing site).4
- Please refer to product labeling for complete information.
LITERATURE SEARCH
A literature search of MEDLINE®
References
| 1 | Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593-3605. |
| 2 | |
| 3 | |
| 4 |
Would you like to clear and leave your conversation? Message history will be lost.